AI Article Synopsis
- GREM1 is linked to tumor progression and poor prognosis in lung adenocarcinoma (LUAD), which is a common and aggressive form of lung cancer.
- The study uses various analyses, including gene expression data and survival analysis, to demonstrate that higher levels of GREM1 are associated with worse patient outcomes and influence the immune microenvironment.
- Experimental results show that GREM1 promotes LUAD cell growth and movement, highlighting its potential as a target for future therapies in personalized cancer treatment.
Article Abstract
Background: Lung adenocarcinoma (LUAD) is a prevalent form of lung cancer globally, known for its high invasiveness, metastatic potential, and notable heterogeneity, particularly in its response to immunotherapy. Gremlin 1 (GREM1) is implicated in tumor progression and poor prognosis in multiple cancers. However, GREM1's specific role in LUAD remains unclear. This study systematically examines GREM1 expression in LUAD and its association with tumor progression, immune microenvironment, and prognosis.
Methods: Gene expression data from the TCGA and GSE31210 databases were analyzed using Weighted Gene Co-expression Network Analysis (WGCNA), GO and KEGG enrichment analyses. The prognostic value of GREM1 was evaluated through survival analysis, Cox regression, and Kaplan-Meier curves. Additionally, immune microenvironment analysis was conducted to explore the relationship between GREM1 and immune cell infiltration. experiments, including Western blot and assays for cell proliferation, migration, and invasion, were performed to confirm the specific role of GREM1 in LUAD cells.
Results: GREM1 was significantly upregulated in tumor tissues and correlated with poor prognosis. Moreover, GREM1 was significantly associated with immune cell infiltration and immunotherapy response within the immune microenvironment. experiments confirmed that GREM1 overexpression significantly promoted LUAD cell proliferation, migration, and epithelial-mesenchymal transition (EMT), whereas GREM1 knockdown suppressed these functions.
Conclusions: A comprehensive analysis indicates that GREM1 is crucial in LUAD progression, with its overexpression predicting poor prognosis. GREM1 could be a potential therapeutic target for LUAD, providing insights for personalized therapy optimization.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11891240 | PMC |
| http://dx.doi.org/10.3389/fimmu.2025.1529195 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Arid4a Suppresses Breast Tumor Metastasis by Enhancing MTSS1 Expression via mRNA Stability.
Cancer Med
March 2025
Institute of Microcirculation, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Background: Tumor metastasis is one of the main causes of death in cancer patients; however, the mechanism controlling metastasis is unclear. The posttranscriptional regulation of metastasis-related genes mediated by AT-rich interactive domain-containing protein 4A (Arid4a), an RNA-binding protein (RBP), has not been elucidated.
Methods: Bioinformatic analysis, qRT-PCR, immunohistochemistry, and immunoblotting were employed to determine the expression of Arid4a in breast tumor tissues and its association with the survival of cancer patients.
Clinical Significance of Bone Metastases in Pleural Mesothelioma.
Thorac Cancer
March 2025
Department of Respiratory Medicine and Hematology, Hyogo Medical University, Nishinomiya, Japan.
Background: Bone metastasis (BoM) is common in advanced cancer, but its incidence in pleural mesothelioma (PM) remains unclear. This study aimed to determine the incidence of BoM in PM patients and assess its prognosis and risk factors to clarify its clinical significance.
Methods: A retrospective analysis was conducted on 515 histologically confirmed PM patients enrolled between January 2011 and December 2020.
Article Synopsis
- The study focused on β2-microglobulin (β2-MG) as a predictor of prognosis in patients with diffuse large B-cell lymphoma (DLBCL), involving 98 patients over two years.
- The critical threshold for β2-MG was identified as 3.285 µg/L, with patients below this level showing better survival rates compared to those above it during follow-up.
- Elevated levels of β2-MG, along with LDH and CRP, were determined to be independent risk factors influencing overall survival in DLBCL patients, leading to the development of a prognostic prediction model that effectively correlated predicted outcomes with actual results.
Background: This study investigated the expression and clinical significance of coiled-coil domain containing 12 (CCDC12) in the initial diagnosis of acute myeloid leukemia (AML).
Methods: A total of 80 AML patients were enrolled as the experimental group, and 20 normal bone marrow specimens were used as the control group. Clinical data of AML patients were collected.
Background: This study aimed to investigate the effects of total antioxidant capacity (T-AOC), superoxide dismu-tase (SOD), and malondialdehyde (MDA) in blood on the postoperative wound healing process of patients with severe burns treated by Meek micrografting.
Methods: In total, 154 patients with severe burns who underwent Meek micrografting treatment were selected as the observation group, and 80 healthy people were taken as the control group. General clinical data were collected, and serum T-AOC, SOD, and MDA were analyzed by biochemical analysis.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!